Who is sponsoring CA225200?

CA225200 is sponsored by US Oncology Research.

What condition does CA225200 study?

CA225200 studies Metastatic Breast Cancer.

What drugs are being tested in CA225200?

Interventions: Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux.

What is the status of CA225200?

CA225200 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2025-01-15 · How we verify

Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer (CA225200)

NCT00248287 Phase 2 ACTIVE_NOT_RECRUITING Results posted

The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.

Details

Lead sponsor	US Oncology Research
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	154
Start date	2005-07-28
Completion	2026-12

Conditions

Metastatic Breast Cancer

Interventions

Irinotecan + Carboplatin
irinotecan + Carboplatin + erbitux

Primary outcomes

Objective Response Rates (ORR) — 2 years
To determine the objective response rates (CR + PR). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Countries

United States